Trial Profile
FAST - A study to evaluate the efficacy and safety of quetiapin[e] IR in patients with acute psychosis.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2011
Price :
$35
*
At a glance
- Drugs Quetiapine (Primary)
- Indications Psychotic disorders
- Focus Therapeutic Use
- Acronyms FAST-A
- Sponsors AstraZeneca
- 09 Dec 2010 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
- 23 Apr 2008 Status changed from recruiting to discontinued, reported by ClinicalTrials.
- 23 Nov 2007 The expected completion date for this trial is now 1 Apr 2008.